Tempo Therapeutics secured $12m in a Series A financing round led by Galaxy Sirius Partners and Johnson & Johnson Innovation – JJDC to advance its synthetic tissue scaffold products into clinical trials.
Tempo Therapeutics secured $12m in a Series A financing round led by Galaxy Sirius Partners and Johnson & Johnson Innovation – JJDC to advance its synthetic tissue scaffold products into clinical trials.
03/20/24, 9:18 AM
Location
san diegoMoney raised
$12 million
Industry
biotechnology
Round Type
series a
Investors
Johnson & Johnson Innovation – Jjdc, Galaxy Sirius Partners
Tempo Therapeutics has closed a $12 million Series A funding round led by Galaxy Sirius Partners and Johnson & Johnson Innovation – JJDC. The funding will enable the company to advance its synthetic tissue scaffold products, TT101 and TT108, into clinical trials and further develop its microporous-annealed-particle (MAP) technology platform for regenerative medicine.
Company Info
Location
3030 bunker hill street
san diego, california, united states
Additional Info
Tempo Therapeutics, headquartered in San Diego, California, is pioneering a new era in tissue engineering biotechnology, using our proprietary MAP material science technology.
Using MAP technology, Tempo is building functional tissue and organs within patients, in real time, to treat disease, and developing next-generation vaccine technologies that are shelf stable, stockpile-able, and protect against multiple diseases with a single injection. Our mission is to use MAP material technology to enable the future of medicine.